These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Clinical Impact of Somatic Variants in Homologous Recombination Repair-Related Genes in Ovarian High-Grade Serous Carcinoma. Choi MC; Hwang S; Kim S; Jung SG; Park H; Joo WD; Song SH; Lee C; Kim TH; Kang H; An HJ Cancer Res Treat; 2020 Apr; 52(2):634-644. PubMed ID: 32019284 [TBL] [Abstract][Full Text] [Related]
23. Distinct homologous recombination gene expression profiles after neoadjuvant chemotherapy associated with clinical outcome in patients with ovarian cancer. Kessous R; Octeau D; Klein K; Tonin PN; Greenwood CMT; Pelmus M; Laskov I; Kogan L; Salvador S; Lau S; Yasmeen A; Gotlieb WH Gynecol Oncol; 2018 Mar; 148(3):553-558. PubMed ID: 29395310 [TBL] [Abstract][Full Text] [Related]
24. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. Konstantinopoulos PA; Spentzos D; Karlan BY; Taniguchi T; Fountzilas E; Francoeur N; Levine DA; Cannistra SA J Clin Oncol; 2010 Aug; 28(22):3555-61. PubMed ID: 20547991 [TBL] [Abstract][Full Text] [Related]
25. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma. Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259 [TBL] [Abstract][Full Text] [Related]
26. Germline mutations in cancer susceptibility genes in high grade serous ovarian cancer in Serbia. Krivokuca A; Boljevic I; Jovandic S; Magic Z; Mandic A; Tomasevic Z; Brankovic-Magic M J Hum Genet; 2019 Apr; 64(4):281-290. PubMed ID: 30651582 [TBL] [Abstract][Full Text] [Related]
27. Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations. Birkbak NJ; Kochupurakkal B; Izarzugaza JM; Eklund AC; Li Y; Liu J; Szallasi Z; Matulonis UA; Richardson AL; Iglehart JD; Wang ZC PLoS One; 2013; 8(11):e80023. PubMed ID: 24265793 [TBL] [Abstract][Full Text] [Related]
28. Germline BRCA mutation carriers are more likely to undergo cytoreductive surgery for relapsed, platinum sensitive, ovarian cancer. Yfat K; Mariam K; Mario B; Hal H; Dana J; Lina S; Ilan B; Gregory P; Limor H Gynecol Oncol; 2022 Nov; 167(2):256-260. PubMed ID: 36154762 [TBL] [Abstract][Full Text] [Related]
29. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. Yang D; Khan S; Sun Y; Hess K; Shmulevich I; Sood AK; Zhang W JAMA; 2011 Oct; 306(14):1557-65. PubMed ID: 21990299 [TBL] [Abstract][Full Text] [Related]
30. The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer. Hjortkjær M; Malik Aagaard Jørgensen M; Waldstrøm M; Ørnskov D; Søgaard-Andersen E; Jakobsen A; Dahl-Steffensen K Int J Gynecol Cancer; 2019 Jan; 29(1):166-173. PubMed ID: 30640700 [TBL] [Abstract][Full Text] [Related]
31. Improved survival in women with BRCA-associated ovarian carcinoma. Cass I; Baldwin RL; Varkey T; Moslehi R; Narod SA; Karlan BY Cancer; 2003 May; 97(9):2187-95. PubMed ID: 12712470 [TBL] [Abstract][Full Text] [Related]
32. Ovarian cancer: Status of homologous recombination pathway as a predictor of drug response. De Picciotto N; Cacheux W; Roth A; Chappuis PO; Labidi-Galy SI Crit Rev Oncol Hematol; 2016 May; 101():50-9. PubMed ID: 26964893 [TBL] [Abstract][Full Text] [Related]
34. BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study. Harter P; Johnson T; Berton-Rigaud D; Park SY; Friedlander M; Del Campo JM; Shimada M; Forget F; Mirza MR; Colombo N; Zamagni C; Chan JK; Imhof M; Herzog TJ; O'Donnell D; Heitz F; King K; Stinnett S; Barrett C; Jobanputra M; Xu CF; du Bois A Gynecol Oncol; 2016 Mar; 140(3):443-9. PubMed ID: 26740259 [TBL] [Abstract][Full Text] [Related]
35. High-risk epithelial ovarian cancer patients for hereditary ovarian cancer. Chirasophon S; Manchana T; Teerapakpinyo C J Obstet Gynaecol Res; 2017 May; 43(5):929-934. PubMed ID: 28188963 [TBL] [Abstract][Full Text] [Related]
36. BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing. Mafficini A; Simbolo M; Parisi A; Rusev B; Luchini C; Cataldo I; Piazzola E; Sperandio N; Turri G; Franchi M; Tortora G; Bovo C; Lawlor RT; Scarpa A Oncotarget; 2016 Jan; 7(2):1076-83. PubMed ID: 26745875 [TBL] [Abstract][Full Text] [Related]
38. Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status. Kotsopoulos J; Rosen B; Fan I; Moody J; McLaughlin JR; Risch H; May T; Sun P; Narod SA Gynecol Oncol; 2016 Jan; 140(1):42-7. PubMed ID: 26556769 [TBL] [Abstract][Full Text] [Related]
39. Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes. da Costa AABA; do Canto LM; Larsen SJ; Ribeiro ARG; Stecca CE; Petersen AH; Aagaard MM; de Brot L; Baumbach J; Baiocchi G; Achatz MI; Rogatto SR BMC Cancer; 2019 May; 19(1):422. PubMed ID: 31060523 [TBL] [Abstract][Full Text] [Related]
40. Genetic Versus Epigenetic BRCA1 Silencing Pathways: Clinical Effects in Primary Ovarian Cancer Patients: A Study of the Tumor Bank Ovarian Cancer Consortium. Sun T; Ruscito I; Dimitrova D; Chekerov R; Kulbe H; Baron U; Blanchard V; Panici PB; Darb-Esfahani S; Sehouli J; Olek S; Braicu EI Int J Gynecol Cancer; 2017 Oct; 27(8):1658-1665. PubMed ID: 28691938 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]